TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in posterior capsule opacification grading score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Imaging Biomarkers of acute cardiac inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of Imaging Biomarkers of late cardiac inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of Imaging Biomarkers of acute cardiac perfusion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of Imaging Biomarkers of late cardiac perfusion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of cardiac fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of BI 754091
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response (OR) - confirmed complete response (CR) or partial response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Day 1 Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life at 3 months after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continued maternal health service utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Institutional Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postnatal Care (PNC 1-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Units of Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for further diagnostic imaging
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of radiation therapy dose escalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of days of pancreatic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 6-Month Progression-Free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Dynamic Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence/absence of a post-voiding residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of medication administration errors
Endpoint domain: Adverse events/effects
Primary endpoint: changed height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 1 Postoperative morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate post-operative technique success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Periostin rate in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail Toxicity of Grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Lisdexamphetamine concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A-a DO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Group A Streptococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Testicular Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Lipoprotein particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Thyroid related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in regional cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in inflammatory markers - hsCRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Calories Taken Orally
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of the Neotree
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the Neotree
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quantitative Usability (Systems usability score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine albumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum creatinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 5-Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Rapid Visual Processing (RVP) Mean Response Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Spatial Working Memory (SWM) Between Errors 4-8 Boxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Stop Signal Task (SST) Stop Signal Reaction T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptoms Improvement by HAMD-17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in Dyspeptic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of actions and steps in the MARCHE RYAN protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rebleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reporting of All Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in caloric compensation in 15 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in eating in the absence of hunger in 15 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained viral response as undetectable level of HCV-RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax,ss of JP-1366, Amoxicillin, Clarithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ of JP-1366, Amoxicillin, Clarithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of grade 3/4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Quantification of DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Safewalker
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Safewalker
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent signal change in the Posterior Cingulate Cortex (PCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Crosser navigation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: WOMAC (total)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical and Radiological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response of primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose (MTD) of decitabine
Endpoint domain: Adverse events/effects
Primary endpoint: NLF-SRS grade of nasolabial folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of the CellSearch® technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of all-cause death/myocardial infarction/stroke/stent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: NRS score in rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Scores From Completeness of Response Survey (CORS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of patients prescribed with VTE prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: subjective symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Meibomian Glands Secretion (MGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder Rate based on GCWS at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-isoprostane levels in exhaled breath condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wheelchair Skills Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal bone level change (MBLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic intracranial haemorrhage (sICH)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent resected volume of pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of stomach erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety knowledge and skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in hand paresis level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from Baseline in hand muscle spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: rate of stroke
Endpoint domain: Mortality/survival
Primary endpoint: maximum tolerated dose of hydroxychloroquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced Adverse Events (AEs) or Serious AE
Endpoint domain: Adverse events/effects
Primary endpoint: Left atrial size changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hoffman reflex latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fibrosis Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of reporting cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Number of absences from daycare/school due to illness
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to First Squamous Cell Carcinoma (SCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Depressive symptoms remission or response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free survival (EFS) for the whole protocol
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival (DFS) R1 + R2
Endpoint domain: Mortality/survival
Primary endpoint: MRD response after 1 cycle of Blinatumomab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dye Leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical benefit (CR, PR, SD lasting > 12 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Quality of Life in Epilepsy-31-Problems (QOLIE-31-P) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Discomfort Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ECOG score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Subjects Satisfying the no Re-fit Criteria in Both Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B lymphocyte and T lymphocyte receptor profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acoustic Signal of Normal Swallowing Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acoustic Signal of Swallowing in the Stroke Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cardiac perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of autonomic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Related haemodynamic variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Experienced Any Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Serum interleukin-1B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum interleukin-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum tumor necrosis factor-a levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum interferon-gamma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation between cytokine status and chronic pulmonary aspergillosis incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postprandial response of glucagon-like peptide-1 (GLP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Radiation exposure for organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Hemoglobin A1c at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline BMI at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Weight at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in American Heart Association's Life's Simple 7 score at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proliferation rate in colon and rectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Progression of Disease or Death
Endpoint domain: Mortality/survival
Primary endpoint: HIV-specific memory T cells (PHPC count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of provision of guideline-based care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC(0-tn) of naproxen sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tn) of DPH HCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of naproxen sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of DPH HCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: identify pathogens in positive blood culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: prevalence of bloodstream infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time from blood collection to pathogen identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPM effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients in Deep Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global cognitive efficiency score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of unanticipated serious adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Bone fusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pathogenesis of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hospitalization for cardiovascular causes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Reduction in the Number of Hand Lentigines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of IV injections of EBV-specific CTLs
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's Global Impression of Therapy of Insomnia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With Objective Tumor Response (OR) to GSK2132231A Study Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Treatment Failure (TTF), by Gene Signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - the maximum plasma concentration - first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - the area under the plasma concentration-time curve from time zero to the last sampling time - first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t½ - the apparent elimination half-life - first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oncotype DX assay results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUClast of Candesartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Impairment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Driving behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent of Behavioral Goals Met
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Dose Limiting Toxicities Per Dosing Level
Endpoint domain: Adverse events/effects
Primary endpoint: ferrous fumarate absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Accuracy of Glucose Concentrations (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Participants Responding 'YES' on the Question Did You Successfully Obtain Measurement Result Using the Dario™ BGMS?
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to occurrence of fatal or non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Remission of calciphylaxis skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: chronic rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: de novo diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Opioid Overdose Knowledge Scale (OOKS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Influenza Cases
Endpoint domain: Adverse events/effects
Primary endpoint: Computerized balance evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of violence control measures utilized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patient injurious behaviors reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in nurse comfort and confidence in their ability to manage patients exhibiting disruptive, threatening or acting out behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Adherence with Study Interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status